Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference
Sight Sciences (Nasdaq: SGHT), a company dedicated to transforming eyecare through innovative technology, has announced its participation in the Bank of America Securities 2023 Health Care Conference in Las Vegas on May 10, 2023, at 3:40pm PT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sight Sciences (Nasdaq: SGHT), a company dedicated to transforming eyecare through innovative technology, has announced its participation in the Bank of America Securities 2023 Health Care Conference in Las Vegas on May 10, 2023, at 3:40pm PT. The event will feature a fireside chat accessible via a live and archived webcast on the company’s investors page. Sight Sciences aims to enhance patient care with its products such as the OMNI® Surgical System for glaucoma and the TearCare® System for dry eye disease. These minimally invasive solutions target the leading causes of eye issues, improving treatment outcomes over traditional methods.
Details
News Market Reaction – SGHT
The recorded move for SGHT in the trading session of this news was +3.17%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced plans to present at the upcoming Bank of America Securities 2023 Health Care Conference in Las Vegas, NV.
Sight Sciences’ management is scheduled to present on Wednesday, May 10, 2023, at 3:40pm PT. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the company’s website at: https://investors.sightsciences.com/.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company’s SION™ Surgical Instrument is a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
For more information, visit www.sightsciences.com.
OMNI and TearCare are registered trademarks of Sight Sciences.
SION is a trademark of Sight Sciences.
© 2023 Sight Sciences. All rights reserved.
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.